Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30712007 | 1.00 | PDE4D (0.41) | PDE4DHSD17B10NPSR1MAPK1ALDH1A1 | |
| SCHEMBL30712011 | 0.88 | PDE4D (0.39) | PDE4DHSD17B10NPSR1MAPK1ALDH1A1 | |
| SCHEMBL21062072 | 0.88 | PDE4D (0.39) | PDE4DHSD17B10NPSR1MAPK1ALDH1A1 | |
| SCHEMBL21130412 | 0.83 | PDE4D (0.44) | PDE4DHSD17B10NPSR1MAPK1ALDH1A1 | |
| SCHEMBL30712013 | 0.83 | PDE4D (0.44) | PDE4DHSD17B10NPSR1MAPK1ALDH1A1 | |
| SCHEMBL23088650 | 0.74 | PDE4D (0.40) | PDE4D | |
| SCHEMBL30712009 | 0.74 | PDE4D (0.40) | PDE4D | |
| SCHEMBL26968847 | 0.68 | PDE4D (0.42) | PDE4DHSD17B10NPSR1MAPK1ALDH1A1 | |
| SCHEMBL30712012 | 0.66 | PDE4D (0.65) | PDE4DMAPK1ALDH1A1TSHR | |
| SCHEMBL21062069 | 0.66 | PDE4D (0.65) | PDE4DMAPK1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981681-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2024-05-14 | — | — | US | disclosed |
| CN-111727191-B | Substituted azetidine dihydro-thienopyridines and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230087354-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2023-03-23 | — | — | US | disclosed |
| EP-3724196-B9 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-03-22 | — | — | EP | disclosed |
| EP-3724196-B1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2022-11-16 | — | — | EP | disclosed |
| EP-3724196-B1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2022-11-16 | — | — | EP | disclosed |
| US-11384096-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-07-12 | — | — | US | disclosed |
| US-11384096-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-07-12 | — | — | US | disclosed |
| US-20210079012-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-18 | — | — | US | disclosed |
| US-20210079012-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-18 | — | — | US | disclosed |
| EP-3724196-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2020-10-21 | — | — | EP | disclosed |
| CN-111727191-A | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-09-29 | — | — | CN | disclosed |
| WO-2019115776-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019115776-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384096-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | PDE2A, PDE3A, PDE3B | PDE4D 12/4885HSD17B10 1658/4885NPSR1 2519/4885 |
| US-11981681-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | PDE2A, PDE3A, PDE3B | PDE4D 12/4885HSD17B10 1658/4885NPSR1 2519/4885 |
| US-20210079012-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE3A, PDE3B | PDE4D 12/4885HSD17B10 1658/4885NPSR1 2519/4885 |
| US-20230087354-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE3A, PDE3B | PDE4D 12/4885HSD17B10 1658/4885NPSR1 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.